Yesterday sort of followed the potential new pattern of gaining strength throughout the day but volumes were a little low as we approach the holiday weekend. I suspect today will be even worse, so I will refrain from making any real interpretations of the moves given the lack of volume. 1. There is a lot […]
April 24 Biotech Update
Some news to talk about today with interesting implications and I will try to cover most of them. The sector seems to be lagging early despite some business development news but we also had a big miss by BIIB that might be acting as a headwind (the M&A rumor seem to save the day so […]
April 17 Biotech Update
The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was it renewed concerns over a Grexit? You would think by now investors are prepared for that potential and/or have been immunized by these repeated concerns. […]
November 26 Biotech Update
The trading is winding down as we approach Thanksgiving and I suspect today is going to be slow and get slower. The market will be open again on Friday but will likely be even slower as many will likely take the half trading day off. I suspect this also means that news flow will also […]
November 20 Biotech Update
Market starts a little weak this morning and generally is taking the sector with it. That being said it is not a rout by any means, so it seems like there sector is looking to find its footing before the next move. Luckily we have some news to talk about. 1. EPZM reported very positive […]
July 11 Biotech Update
Despite a weak macro market, biotechs actually performed pretty well yesterday. That was a surprise albeit a pleasant one. Clearly biotech has its mojo back as three or four months ago, the sector would have been down 5% on a day like yesterday. I have been talking about reactions to earnings as a signal about […]
June 4 Biotech Update- The Post-ASCO Blue
So another ASCO is in the books and it seems like a fairly bland conference with relatively few significant stock reactions. Over the next couple of days I will sort out both what I saw as the major themes in the data but also the elusive “buzz.” In other words, there are the facts as […]
May 21 Biotech Update- A Little More Drama
It was a quiet day in the market. The sector started off well but it seemed to simply be following the broader market. I still think we are unfortunately tied to the macro and that the next move in the sector will be with the market. It could be that if the move is down […]
May 19 Biotech Update- The Merger Drama
It was certainly an interesting start to the week in terms of the PFE/AZN drama but the price action outside of those names was somewhat muted (I guess also outside the ITMN move). My point is that outside the names directly related to news, there was nothing significant and more of a trending day (with […]
May 15 Biotech Update- The ASCO Deluge Begins
So there is a lot to talk about with the ASCO abstracts and I will divide this up over a couple of days (I am trying to write quickly to get this out so excuse typos and poor grammar for the next couple of days). In general, I think the sense is that these are […]
May 5 Biotech Update
Really not a lot to talk about today. The sector had a decent morning but news flow was relatively low outside of the PFE call. Even that was a little anti-climatic as it did not really add anything that we did not already know. They made the case that an AZN deal does not destroy […]
April 28 Biotech Update- Turning Up the M&A Speculation
It was another interesting and good start to the week (until we got into the usual late morning selling). In fact, it seems like we were just talking about a PFE offer for AZN last Monday (oh, wait we were). Is this the reason that the sector is stronger or are we simply getting an […]
Dissecting the ASCO 2014 abstract titles
Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014 is scheduled to take place from May 30th to June 3rd, 2014. Below we list some of our observations on the oral abstracts. We have […]
April 21 Biotech Update- Some Good News to Start the Week
You would think the morning after a holiday would not be too busy but I have been running around all morning trying to organize a number of different projects. Luckily there are really only two issues that I wanted to address today as they have import for both individual stocks but also perhaps for the […]
December 18 Daily Biotech Update- A Couple of Surprises
Well, the taper was exactly what the market and biotech sector need. Who saw that one coming? Is this simply a relief rally, start of a Santa rally, or setting us up for a bigger fall? For the biotech sector I see it more as a relief rally at this point but one that may […]
TSRO – A look at Tesaro
Following additional information released at ASCO 2013 and their recent quarterly updated, we wanted to take a moment to talk about Tesaro (TSRO). Since their IPO, Tesaro’s stock is up roughly 186% at a fully diluted marketcap of $1.22 billion (@ $35 per share) based on roughly 35 million shares outstanding. Tesaro’s pipeline consists of […]
Datasets in focus at IASLC this weekend
This weekend is the 15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th (Site). Abstracts can be found here. In particular, we want to speak briefly about 7 presentations. PD1 inhibitors Bristol-Myers (BMY), Merck (MRK) and Roche (RHHBY) […]
October 15- EOD
While this may surprise you (not) but it was another macro driven day (I know you are probably getting as tired of reading that as I am of writing it). Volume also seems to be drying up as investor simply sit on their hands and wait for Washington to get off of their hands. Despite […]
What to look for at ESMO 2013
Apropos to our post yesterday on upcoming medical conferences, we wanted to begin with some coverage of the European Cancer Congress 2013 (ECCO-ESMO). This conference takes place Friday, September 27th thru Tuesday, October 1st. Below we have some of the datasets and updates we are looking forward to seeing. ESMO planners also put out their, […]
Upcoming earnings and conferences this week
With the first quarter behind us, we look to updates across the biotech industry on new product launches and guidance for the year. We are also coming upon the summer medical conference series. Additionally, we briefly discuss 2 upcoming FDA approvals. Upcoming earnings releases and updates Monday, April 22nd After-Hours: ILMN Tuesday, April 23rd Pre-Market: […]
